{"created":"2023-05-15T12:16:43.427176+00:00","id":375,"links":{},"metadata":{"_buckets":{"deposit":"b158b5cc-1f43-40bb-8435-59913fd8f4b2"},"_deposit":{"created_by":4,"id":"375","owners":[4],"pid":{"revision_id":0,"type":"depid","value":"375"},"status":"published"},"_oai":{"id":"oai:aino.repo.nii.ac.jp:00000375","sets":["7:42"]},"author_link":["1178"],"item_3_biblio_info_12":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2012-03-31","bibliographicIssueDateType":"Issued"},"bibliographicVolumeNumber":"10","bibliographic_titles":[{},{"bibliographic_title":"Aino journal","bibliographic_titleLang":"en"}]}]},"item_3_description_11":{"attribute_name":"抄録(英)","attribute_value_mlt":[{"subitem_description":"Chronic myeloid leukemia (CML) was once a life-threatening disease in which the clonal expansion of leukemic myeloid cells occurs as a result of reciprocal chromosomal translocation between long arm of chromosome 9 and 22 (Philadelphia chromosome). The resulting fusion protein BCR-ABL shows constantly activated ABL tyrosine kinase activity which is essential for growth of leukemic cells. Specific inhibition of this activated tyrosine kinase by imatinib (Gleevec, Novartis) has completely changed the curability of the disease (Druker et al., 2001). Imatinib is designed to inhibit the binding of ATP to the ABL tyrosine kinase so as to abolish the phosphorylation of the downstream signal proteins. Chronic myeloid leukemia is one of the diseases of which the molecular mechanism of development has been best dissected. And the discovery of imatinib is truly a milestone and the victory for modern molecular medicine. Its amazing efficacy has transformed a disease with a formidable prognosis, CML, into a chronic condition with safety well established. Imatinib now being a standard therapy for CML, the history of the study of the molecular mechanism of CML, the discovery of the drug, and the related questions are discussed. ","subitem_description_type":"Other"}]},"item_3_description_15":{"attribute_name":"表示順","attribute_value_mlt":[{"subitem_description":"5","subitem_description_type":"Other"}]},"item_3_description_16":{"attribute_name":"アクセション番号","attribute_value_mlt":[{"subitem_description":"KJ00008182379","subitem_description_type":"Other"}]},"item_3_description_2":{"attribute_name":"ページ属性","attribute_value_mlt":[{"subitem_description":"P","subitem_description_type":"Other"}]},"item_3_description_9":{"attribute_name":"記事種別(英)","attribute_value_mlt":[{"subitem_description":"Review article","subitem_description_type":"Other"}]},"item_3_source_id_1":{"attribute_name":"雑誌書誌ID","attribute_value_mlt":[{"subitem_source_identifier":"AA11877461","subitem_source_identifier_type":"NCID"}]},"item_3_source_id_19":{"attribute_name":"ISSN","attribute_value_mlt":[{"subitem_source_identifier":"1348480X","subitem_source_identifier_type":"ISSN"}]},"item_3_text_7":{"attribute_name":"著者所属(英)","attribute_value_mlt":[{"subitem_text_language":"en","subitem_text_value":"Department of Physical Therapy,Faculty of Nursing and Rehabiitation,Aino University"}]},"item_3_title_3":{"attribute_name":"論文名よみ","attribute_value_mlt":[{"subitem_title":"Breakthrough in the treatment of chronic myeloid leukemia"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"YAMADA, Yoshihiro","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"1178","nameIdentifierScheme":"WEKO"}]}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2019-03-27"}],"displaytype":"detail","filename":"KJ00008182379.pdf","filesize":[{"value":"411.0 kB"}],"format":"application/pdf","licensetype":"license_note","mimetype":"application/pdf","url":{"label":"KJ00008182379.pdf","url":"https://aino.repo.nii.ac.jp/record/375/files/KJ00008182379.pdf"},"version_id":"7205b2d1-0f69-4994-8a48-efc75cc587a9"}]},"item_keyword":{"attribute_name":"キーワード","attribute_value_mlt":[{"subitem_subject":"CML","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"Philadelphia chromosome","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"BCR-ABL","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"tyrosine kinase","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"imatinib","subitem_subject_language":"en","subitem_subject_scheme":"Other"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"eng"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"departmental bulletin paper","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"Breakthrough in the treatment of chronic myeloid leukemia","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"Breakthrough in the treatment of chronic myeloid leukemia","subitem_title_language":"en"}]},"item_type_id":"3","owner":"4","path":["42"],"pubdate":{"attribute_name":"公開日","attribute_value":"2019-03-27"},"publish_date":"2019-03-27","publish_status":"0","recid":"375","relation_version_is_last":true,"title":["Breakthrough in the treatment of chronic myeloid leukemia"],"weko_creator_id":"4","weko_shared_id":4},"updated":"2023-05-15T16:02:40.858798+00:00"}